Indo Us Biotech Limited has informed the Exchange about Copy of Newspaper Publication for unaudited financial results for the quarter ended on 30-06-2025
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indo Us Biotech Limited submitted copies of its newspaper advertisement (published in Western Times – English and Gujarati) for the unaudited standalone financial results of Q1 FY26, in compliance with SEBI LODR Regulation 47. Total income from operations stood at ₹3,077.11 lakhs, up about 24% from ₹2,474.57 lakhs in the same quarter last year. Profit before tax rose to ₹481.99 lakhs (vs ₹318.82 lakhs in Q1 FY25), and net profit jumped roughly 48% to ₹470.24 lakhs (vs ₹316.86 lakhs). Basic and diluted EPS for the quarter came in at ₹2.35, compared to ₹1.58 in the year-ago quarter. The underlying results were already approved by the Board on 12 August 2025; this filing is purely a regulatory disclosure of the published advertisement.
Strong year-on-year growth in both revenue (~24%) and net profit (~48%) signals healthy business momentum, which is positive for shareholders. The filing itself is a routine compliance disclosure and unlikely to trigger any direct stock price reaction beyond reinforcing the Q1 earnings story.